Hadassah

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Wednesday, Jan 10 2018

Illustration of the positive impact of Namodenoson, as compared to treatment of animals with a placebo (“vehicle”)

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

The new drug called Namodenoson, Dr. Safadi says, “is unique among today’s NASH drugs under development due to its excellent safety profile and the positive effect on steatosis (accumulation of fat in the liver), inflammation, and fibrosis (liver scarring, which results from dying of liver cells, also referred to as ballooning).”  Improvement in these parameters translates into a significant anti-NASH effect.

Namodenoson has been granted Orphan Drug Designation in the United States and Europe and Fast Track Designation as a second-line treatment for hepatocellular cancer by the United States Food and Drug Administration. It has the potential to be effective in treating other cancers, including colon and prostate cancer, as well as melanoma.

Can-Fite has initiated enrollment for a Phase II study with Namodenoson in NASH and NAFLD (non-alcoholic fatty liver disease) patients who show evidence of active inflammation. The focus will be on measuring the drug’s anti-inflammatory effect and its success in reducing fat in the liver.

A prolific researcher, renowned for his work with NASH, Dr. Safadi is also a member of Can-Fite’s Clinical Advisory Board. “We are privileged to work with Dr. Safadi to further study and advance the drug’s mechanism of action,” notes Pnina Fishman, PhD, Founder and Chief Executive Officer of Can-Fite.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Apr 17 2018

Where are we with Stem Cells? Hadassah Pioneer Brings Us Up to Date

Many diseases involve the malfunctioning or dying of cells within the body.

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›
alt_text

Friday, Apr 13 2018

Hadassah Hospital Mount Scopus Hosts Conference to Mark Annual World Down Syndrome Day

Hadassah Hospital Mount Scopus hosted 200 people at the annual World Down Syndrome Day conference, held at the hospital in late March.

READ MORE ›
alt_text

Friday, Apr 13 2018

Hadassah Physicians Increase Number of Partial Thyroidectomies Following New ATA Guidelines

Following updated recommendations from the American Thyroid Association (ATA), Nir Hirschoren, M.D., of the Hadassah-Hebrew University Medical Center in Jerusalem...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More